Is Wegovy pill better than Zepbound injections?

Both are effective; Wegovy is oral while Zepbound is injectable. Choice depends on patient preference.

Why has Novo Nordisk stock fallen despite Wegovy's success?

The stock faced pressure from price cuts and regulatory concerns, but prescription numbers may support a recovery.

What is Novo Nordisk's strategy for Wegovy?

The company focuses on increasing sales volume to offset price cuts, supported by prescription numbers.

Novo Nordisk's Wegovy Pill Hits 3 Million Prescriptions

Novo Nordisk announced that its Wegovy pill has surpassed 3 million prescriptions, reinforcing management's view that volume growth will offset price cuts. The stock remains beaten down, raising questions about Wall Street's valuation.

June 20, 2026

2 min read

Source: Motley Fool

Key Numbers

prescriptions

3 million

Novo Nordisk (NYSE: NVO) announced that its weight-loss pill Wegovy has surpassed 3 million prescriptions, signaling strong demand for the oral treatment. The milestone comes as the company continues to focus on volume growth to offset price cuts that have weighed on revenue.

Details of the Announcement

Novo Nordisk confirmed that Wegovy, which contains the active ingredient semaglutide, has become a popular choice among patients. The 3 million prescriptions represent cumulative totals since launch, reflecting broad market acceptance.

Context

Novo Nordisk faces intense competition from Eli Lilly (NYSE: LLY) in the obesity drug market. While Lilly focuses on Zepbound injections, Novo offers an oral alternative that may appeal to some patients. However, NVO stock has faced pressure due to price cuts and regulatory concerns.

What It Means for Investors

The prescription numbers suggest that the volume-for-price strategy may be working. If Wegovy demand continues to grow, the stock could improve. However, investors should also watch competitive and pricing developments.

Frequently Asked Questions

Novo Nordisk's Wegovy pill has surpassed 3 million prescriptions.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.